| 2014CG023 |
Chemotherapy;Other Cancer Trea |
Phase I/II
|
COG ADVL1312 - A Phase 1/2 Study OF AZD1775 (MK-1775 , IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
|
| 2014IS062 |
Chemotherapy |
Phase I/II
|
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutation (MEK116540)
|
| 2014IS090 |
Immunotherapy - Cellular/Vacci |
Phase I/II
|
A Phase I/II safety, pharmacokinetic, and pharmacodynamic study of APS001F with flucytosine and maltose for the treatment of advanced and/or metastatic solid tumors.
|
| 2015CG012 |
Chemotherapy |
Phase I/II
|
COG ADVL1412 - A Phase 1/2 Study of Nivolumab (IND# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Additional Title: ADVL1412-Bristol-Myers Squibb Company
|
| 2015LS057 |
Immunotherapy - Cellular/Vacci |
Phase I
|
MT2015-46 : A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
|
| 2015IS075 |
Immunotherapy - Drugs |
Phase I/II
|
HM2015-18: A phase 1/2 study of ALT-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab
|
| 2015CG151 |
Other Cancer Treatment;Surgery |
Phase I
|
ADVL1414 - A PHASE 1 STUDY OF SELINEXOR (KPT-330, IND #125052), A SELECTIVE XPO1 INHIBITOR, IN RECURRENT AND REFRACTORY PEDIATRIC SOLID TUMORS, INCLUDING CNS TUMORS
|
| 2016IS002 |
Chemotherapy;Other Cancer Trea |
Phase I
|
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors (I5B-MC-JGDN)
|
| 2016UC011 |
Immunotherapy - Drugs |
Phase I/II
|
A Phase IB/II study of nivolumab in combination with ALT-803 in patients with pretreated, advanced or metastatic non-small cell lung cancer
|
| 2016IS065 |
Immunotherapy - Drugs |
Phase I
|
An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
|
| 2016CG135 |
Supportive Care |
Pilot
|
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma) ALLIANCE A221504
|
| 2016LS153 |
Immunotherapy - Cellular/Vacci |
Phase I
|
MT2016-27 Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) with Subcutaneous IL-2 in Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML)
|
| 2016LS186 |
Immunotherapy - Cellular/Vacci |
Phase I
|
MT2017-14 :Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) with Intraperitoneal Interleukin-2 in Women with Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
|
| 2016IS192 |
Immunotherapy - Cellular/Vacci |
Phase I
|
A Phase 1, Open-Label, Multicenter, Dose escalation study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection to patients with advanced malignancies
|
| 2016IS191 |
Chemotherapy |
Phase I
|
A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents With No Curative First-Line Treatment Option, Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With Or Without TRK, ROS1, or ALK Fusions
|
| 2016CG156 |
Chemotherapy |
Phase I
|
COG ADVL1513 - A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
|
| 2017LS006 |
Immunotherapy - Drugs |
Phase I
|
HM2017-24 :Phase I Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma
|
| 2017IS028 |
Immunotherapy - Cellular/Vacci |
Phase I
|
Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFNβ-NIS), in Patients with Refractory Solid Tumors
|
| 2017CG036 |
Chemotherapy |
Phase I
|
COG ADVL1515 - A Phase 1 Study of LY2606368 (prexasertib mesylate monohydrate) (IND#132233) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Added Title: "ADVL1515 - Eli Lilly and Company "
|
| 2017IS061 |
Immunotherapy - Cellular/Vacci |
Phase I
|
MT2017-36 :FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors
|
| 2017IS100 |
Immunotherapy - Cellular/Vacci |
Phase I
|
HM2017-31: Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20+ B Cell Lymphoma
|
| 2017UC122 |
Hormone Therapy |
Pilot
|
Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
|
| 2017CG143 |
Chemotherapy |
Phase I
|
COG ADVL1615 - A Phase I Study of Pevonedistat (MLN-4924, IND#136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
Additional Title: "COG ADVL1615 - Millennium Pharmaceuticals, Inc."
|
| 2017IS140 |
|
Phase I/II
|
A phase 1B/2 study to evaluate safety and anti-tumor activity of avelumab in combination with the poly (adenosine diphosphate [adp]-ribose) polymerase (parp) inhibitor talazoparib in patients with locally advanced or metastatic solid tumors
|
| 2018CG009 |
Other Cancer Treatment |
Phase I/II
|
COG ADVL1614 - A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
Additional Funding Title - "ADVL1212 Study Chair NIH COG Phase 1 Grant (UMCA097452)"
|
| 2018IS003 |
Immunotherapy - Drugs |
Phase I/II
|
A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH NKTR-214 AND IN COMBINATION WITH NKTR-214 PLUS NIVOLUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
|
| 2018CG028 |
|
Phase I/II
|
A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration Resistant Prostate Cancer
|
| 2018IS018 |
Immunotherapy - Drugs |
Phase I/II
|
A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent / Metastatic Human Papilloma Virus Associated Head and Neck Squamous Cancer
|